Ocuphire Pharma Future Growth
Future criteria checks 5/6
Ocuphire Pharma is forecast to grow earnings and revenue by 9.5% and 28.5% per annum respectively while EPS is expected to grow by 15.6% per annum.
Key information
9.5%
Earnings growth rate
15.6%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 28.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Apr 2024 |
Recent future growth updates
Recent updates
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11Ocuphire drops 11% on $15M at-the money direct offering
Jun 04Ocuphire Pharma EPS beats by $0.36
May 07Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?
Feb 08Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition
Jan 06Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances
Jan 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 40 | -28 | -26 | N/A | 3 |
| 12/31/2025 | 72 | 40 | -6 | 134 | 4 |
| 12/31/2024 | 28 | -1 | -20 | 27 | 4 |
| 12/31/2023 | 19 | -10 | -1 | -1 | N/A |
| 9/30/2023 | 57 | 29 | 23 | 23 | N/A |
| 6/30/2023 | 45 | 19 | 22 | 22 | N/A |
| 3/31/2023 | 42 | 19 | 17 | 17 | N/A |
| 12/31/2022 | 40 | 18 | 14 | 14 | N/A |
| 9/30/2022 | N/A | -22 | -20 | -20 | N/A |
| 6/30/2022 | 0 | -22 | -19 | -19 | N/A |
| 3/31/2022 | 1 | -24 | -20 | -20 | N/A |
| 12/31/2021 | 1 | -57 | -19 | -19 | N/A |
| 9/30/2021 | 1 | -69 | -20 | -18 | N/A |
| 6/30/2021 | 0 | -66 | -17 | -16 | N/A |
| 3/31/2021 | N/A | -61 | -13 | -12 | N/A |
| 12/31/2020 | N/A | -25 | -8 | -7 | N/A |
| 9/30/2020 | N/A | -8 | -4 | -4 | N/A |
| 6/30/2020 | N/A | -9 | -4 | -4 | N/A |
| 3/31/2020 | N/A | -8 | -4 | -4 | N/A |
| 12/31/2019 | N/A | -6 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCUP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: OCUP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OCUP is expected to become profitable in the next 3 years.
Revenue vs Market: OCUP's revenue (28.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: OCUP's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCUP's Return on Equity is forecast to be high in 3 years time